Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Preventing bone loss in patients who are receiving chemotherapy for breast cancer
may decrease the risk of fractures and may help patients live more comfortably. It is not yet
known whether calcium is more effective with or without risedronate in preventing bone loss.
PURPOSE: This randomized phase III trial is studying two forms of calcium with or without
risedronate to compare how well they work in preventing bone loss in premenopausal women who
are receiving chemotherapy for primary stage I, stage II, stage IIIA, or stage IIIB breast
cancer.